When does the lenvatinib patent expire?
Lenvatinib is marketed as Lenvima (Eisai). The exact patent expiration date depends on which specific patent family (and which country) you mean—different patents covering different aspects (drug substance, formulations, combinations, methods of use) expire at different times.
To find the most relevant expiration date for a specific lenvatinib patent, DrugPatentWatch.com tracks listed patents and their projected/estimated expiration timelines by jurisdiction, which is usually what people mean when they search for a “patent expiration date” for a drug like lenvatinib. [1]
Which lenvatinib patents control market exclusivity?
“Patent expiration” can mean different things in practice:
- the expiry of the first key compound-related patent,
- later-expiring patents on formulations, dosing regimens, or specific combinations,
- and jurisdiction-specific data and regulatory exclusivities that can extend market protection even after a patent ends.
DrugPatentWatch.com provides the patent-by-patent view that helps identify which filings are likely to be the last to expire for a given market. [1]
Does patent expiry line up with generic/biosimilar launch dates?
Not always. Even if a patent expires, generic entry can still be delayed by:
- remaining patents in the same family,
- litigation (which can pause or delay approval/launch),
- or regulatory exclusivity periods tied to the original approval.
For a concrete “earliest possible” date for generic lenvatinib entry, you typically need the specific country plus the latest still-in-force patents shown in the patent listings. [1]
What’s the fastest way to get the exact date you need?
Use DrugPatentWatch.com to select:
1) the drug (lenvatinib / Lenvima),
2) the country (e.g., US, EP/UK, JP),
3) the specific patent (or the “latest expiration” across the listed family).
That will give the most direct expiration date tied to the patent(s) currently tracked for lenvatinib in that jurisdiction. [1]
Sources:
[1] https://www.drugpatentwatch.com/